On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
Hung‐Wei Wang(China Medical University), Cheng‐Yuan Peng(China Medical University), Po‐Heng Chuang(China Medical University), Tsung‐Hui Hu(National Sun Yat-sen University), Jing‐Houng Wang(Chang Gung University), Mei–Hsuan Lee(National Taiwan University), Chia‐Hsin Lin(Chang Gung University), Wen-Pang Su(China Medical University), Hsueh‐Chou Lai(China Medical University), Chien‐Hung Chen(Chang Gung University), Chao‐Hung Hung(Chang Gung University), Sheng‐Nan Lu(Chang Gung University)
Cited by 14
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653